Get the Stockscreener App
22.54
0.66%
-0.11
Enliven Therapeutics Inc stock is currently priced at $22.54, with a 24-hour trading volume of 178.10K.
It has seen a -0.66% decreased in the last 24 hours and a +15.98% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $22.33 pivot point. If it approaches the $23.32 resistance level, significant changes may occur.
Previous Close:
$22.65
Open:
$22.88
24h Volume:
178.10K
Market Cap:
$1.07B
Revenue:
-
Net Income/Loss:
$-71.58M
P/E Ratio:
-18.16
EPS:
-1.2413
Net Cash Flow:
$-61.42M
1W Performance:
+26.48%
1M Performance:
+15.98%
6M Performance:
+82.93%
1Y Performance:
+14.56%
1D Range:
$22.40
$22.91
52W Range:
$9.80
$26.00
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720 647 8519
Address
6200 Lookout Road, Boulder
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-29-23 | Initiated | Jefferies | Buy |
Enliven Therapeutics Inc Stock (ELVN) Latest News
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
Benzinga
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
GlobeNewswire Inc.
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
GlobeNewswire Inc.
Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says
Benzinga
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
GlobeNewswire Inc.
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Enliven Therapeutics Inc (ELVN) Net Income 2024
ELVN net income (TTM) was -$71.58 million for the quarter ending December 31, 2023, a -90.07% decrease year-over-year.
Enliven Therapeutics Inc (ELVN) Cash Flow 2024
ELVN recorded a free cash flow (TTM) of -$61.42 million for the quarter ending December 31, 2023, a -87.89% decrease year-over-year.
Enliven Therapeutics Inc (ELVN) Earnings per Share 2024
ELVN earnings per share (TTM) was -$1.7382 for the quarter ending December 31, 2023, a -89.68% decline year-over-year.
Enliven Therapeutics Inc Stock (ELVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hohl Benjamin | CHIEF FINANCIAL OFFICER |
Apr 29 '24 |
Option Exercise |
2.48 |
3,250 |
8,060 |
3,250 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER |
Apr 29 '24 |
Sale |
17.92 |
12,000 |
214,988 |
0 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER |
Apr 29 '24 |
Sale |
16.97 |
3,250 |
55,165 |
0 |
| Kintz Samuel | PRESIDENT AND CEO |
Apr 25 '24 |
Option Exercise |
1.12 |
12,000 |
13,440 |
12,000 |
| Kintz Samuel | PRESIDENT AND CEO |
Apr 25 '24 |
Sale |
16.89 |
12,000 |
202,700 |
0 |
| Heyman Richard A. | Director |
Apr 15 '24 |
Sale |
19.99 |
1,270 |
25,383 |
137,155 |
| Ballal Rahul D. | Director |
Apr 11 '24 |
Option Exercise |
13.21 |
53,400 |
705,266 |
75,741 |
| Kintz Samuel | PRESIDENT AND CEO |
Apr 11 '24 |
Option Exercise |
1.12 |
47,709 |
53,434 |
47,709 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER |
Apr 11 '24 |
Option Exercise |
2.48 |
20,000 |
49,600 |
20,000 |
| Patel Anish | CHIEF OPERATING OFFICER |
Apr 11 '24 |
Option Exercise |
2.48 |
14,903 |
36,959 |
17,500 |
About Enliven Therapeutics Inc
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
0.33%
0.92%
Cap:
|
Volume (24h):